OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2016.4362 OL-0-0-4362 Articles Oxidored-nitro domain-containing protein 1 expression is associated with the progression of hepatocellular carcinoma LIDENG-QING 1 QIUMING 1 NIEXIN-MIN 2 GUIRONG 2 HUANGMIN-ZHU 3 Department of Laboratory Medicine, Xiangya Medical School, Central South University, Changsha, Hunan 410013, P.R. China Clinical Laboratory Centre of The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China Public Health School of Central South University, Changsha, Hunan 410078, P.R. China Correspondence to: Dr Ming Qiu, Department of Laboratory Medicine, Xiangya Medical School, Central South University, 138 Tongzipo Road, Changsha, Hunan 410013, P.R. China, E-mail: qiu_ming@yeah.net Dr Xin-Min Nie, Clinical Laboratory Centre of The Third Xiangya Hospital, Central South University, 138 Tongzipo Road, Changsha, Hunan 410013, P.R. China, E-mail: niexm6918@163.com 05 2016 22 03 2016 11 5 3003 3008 14022015 04032016 Copyright: © Li et al. 2016 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Hepatocarcinogenesis is a stepwise process during which multiple genes are altered. Understanding the molecular mechanisms that induce hepatocarcinogenesis may improve the screening, prevention and treatment of patients with hepatocellular carcinoma (HCC). In recent years, the oxidored-nitro domain-containing protein 1 (NOR1) gene has been identified to have an important role in the development of HCC in vitro experiments. The current study aimed to examine the expression of NOR1 mRNA and protein expression in specimens of normal liver, hepatitis, cirrhosis and HCC, together representing the process of HCC development. Furthermore, the association between NOR1 expression and clinicopathological parameters of HCC patients was analyzed. Tissue microarrays containing the specimens of human normal liver, hepatitis, cirrhosis and HCC were purchased, and in situ hybridization and immunohistochemistry were used to detect the expression of NOR1 mRNA and protein expression, respectively. It was revealed that the positive rate of NOR1 protein and mRNA expression in the specimens of hepatitis and cirrhosis were not significantly different from that in the normal liver samples. However, the specimens of HCC exhibited an increased positive rate of NOR1 protein and mRNA expression in comparison with the normal liver samples. In addition, a higher positive rate of NOR1 protein expression was observed in HCC patients with a poor pathological differentiation grade and high tumor node metastasis (TNM) stage. In conclusion, the present study provides evidence, for the first time, of the increased expression of NOR1 in human HCC tissues, and its correlation with the pathological stage and TNM status. These findings indicate that NOR1 may be involved in the progression of HCC and it could be employed as a predictive biomarker in HCC development.

 oxidored-nitro domain-containing protein 1 hepatocellular carcinoma hepatitis cirrhosis clinicopathological parameters Introduction

Hepatocellular carcinoma (HCC) accounts for 85–90% cases of primary liver cancer (1). It is the fifth most common malignancy and the third leading cause of cancer-related mortality worldwide (1–3). The epidemiological characteristics of liver cancer differ between various countries; for example, ~85% of cases of liver cancer occur in developing countries and 54% occur in China (4). Furthermore, >80% of patients with HCC have a history of hepatitis or cirrhosis, and HCC generally has a poor prognosis (1,5–7). The majority of patients with HCC are present and are diagnosed in the advanced stages of the disease (5), and no effective chemotherapy or radiotherapy exists for the advanced disease. Surgical resection is effective only in the early stages of HCC, however, the 5-year survival rate is as low as 25–39% following surgery (8). It has been demonstrated that multiple genes are altered during the process of hepatocarcinogenesis (9). Understanding the molecular mechanisms that induce hepatocarcinogenesis may improve the screening, prevention and treatment of patients with HCC (10).

Oxidored-nitro domain-containing protein 1 (NOR1) gene is a nitroreductase (NTR) gene that was initially isolated from nasopharyngeal carcinoma (NPC) (11). The NOR1 gene encodes two transcripts and acts as a candidate tumor repressor gene associated with NPC. It has a similar activity to bacterial NTR, which converts 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954), a monofunctional alkylating agent, into a toxic form. A previous study supported the hypothesis that NOR1 is involved in the chemical carcinogenesis of hepatic cancer. NOR1 overexpression increased the expression levels of growth factor receptor-bound protein 2 (Grb2) mRNA and protein in HepG2 cells, and activated mitogen-activated protein kinase (MAPK) signal transduction, thus leading to enhanced CB1954-induced cell killing in HepG2 cells (12). Furthermore, DNA microarray data suggested that overexpression of NOR1 protein results in altered gene expression profiles in HepG2 cells, including 59 upregulated genes and 103 downregulated genes (13). These findings indicate that the NOR1 gene may have an important role in the development of HCC.

The present study examined, for the first time, the expression levels of NOR1 mRNA and protein in specimens of human normal liver, hepatitis, cirrhosis and HCC, together representing the process of HCC development. In addition, the association, between NOR1 expression and clinicopathological parameters of HCC patients was investigated. The present study may facilitate in elucidating the role of NOR1 expression in liver carcinogenesis. The study was approved by the Ethics Committee of The Third Xiangya Hospital, Central South University (Changsha, Hunan, China).

 Materials and methods <sec> <title>Tissue microarrays

Sections (5 µm) of formalin-fixed, paraffin-embedded tissue microarrays (cat. no. LV20812) were purchased from US Biomax, Inc. (Rockville, MD, USA). The tissue microarray contained 16 samples of normal human liver, 24 samples of hepatitis, 32 samples of cirrhosis and 32 samples of HCC. Sections were arranged in duplicate cores per sample.

 In situ hybridization (ISH)

The formalin-fixed paraffin-embedded sections were baked at 60°C for 30 min, then deparaffinized by immersing in xylene (Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) for 15 min twice. After immersing in 100% ethanol (Sinopharm Chemical Reagent Co., Ltd.) for 5 min, the slides were air-dried and then incubated with pepsin (Coolaber Technology Co., Ltd., Beijing, China) at 37°C for 30 min. Digoxigenin-labeled RNA probes were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). The sequences were as follows: 5′-CTAAGTTCTTTGATGATCCAGACACATGAGTTTCCACAGGCTGATTCACGCT-3′dig. The probes were diluted in prewarmed hybridization buffer (Wuhan Boster Biological Tehnology Ltd.., Wuhan, Hubei, China) to a concentration of 10 ng/µl and added to the slides for incubation at 37°C overnight. The slides were washed with saline-sodium citrate and Tris-buffered saline (both Coolaber Technology Co., Ltd.,), then incubated with mouse anti-digoxygenin monoclonal antibody (1:200 dilution; cat. no. ab119345; Abcam, Cambridge, MA, USA) at 4°C overnight. For signal development, nitroblue tetrazolium and bromochloroindolyl phosphate were used for staining at 37°C for 30 min, and nuclear fast red dye served as the counterstain at 37°C for 1–2 min (all Sigma-Aldrich, St. Louis, MO, USA).

 Immunohistochemistry (IHC)

The sections were baked at 60°C for 30 min followed by deparaffinization in xylene and rehydrated with graded ethanol. Antigen retrieval was performed by heating the sections in 0.01 M citrate buffer (Coolaber Technology Co., Ltd.) for 2 min, then adding 3% H2O2/methanol solution (Sinopharm Chemical Reagent Co., Ltd.) to quench endogenous peroxidase. The sections were subsequently incubated with goat anti-NOR1 polyclonal antibody (1:50 dilution; cat. no. sc-161980; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at 4°C overnight. After washing with 0.1% Tween-20/phosphate-buffered saline (Coolaber Technology Co., Ltd.), Polymer Helper (ZSGB-BIO, Beijing, China) was added to the sections and incubated at room temperature for 15 min. The sections were washed for three times and then incubated with horseradish peroxidase-conjugated anti-goat IgG (1:2,000 dilution; cat. no. PV-9003; ZSGB-BIO) at room temperature for 15 min. The slides were stained using a DAB staining kit (Fuzhou Maixin Biotech Co., Ltd., Fuzhou, China) and counterstained with hematoxylin (Beyotime Institute of Biotechnology, Shanghai, China) at 37°C for 3–5 min.

 Scoring method

The present study used the same semiquantitative scoring method for ISH and IHC (14,15). The sections were semiquantitatively analyzed independently by two pathologists. All staining was observed using an E200 microscope (Nikon, Tokyo, Japan). The staining intensity was scored as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong). The staining density score was based on the percentage of positive cells, as follows: 0 (0%), 1 (1–10%), 2 (11–50%), 3 (51–80%) and 4 (81–100%). The staining intensity and density scores were multiplied and used as the overall score. An overall score of >3 was considered to indicate positive NOR1 expression; scores of ≤3 indicated negative NOR1 expression.

 Statistical analysis

Statistical analysis was performed using SPSS software (version 19.0; IBM SPSS, Chicago, IL, USA). Data are representative of at least three independent experiments. Pearson's χ2 test and Fishers exact test were performed to compare differences between groups. P<0.05 was considered to indicate a statistically significant.

 Results <sec> <title>Expression of NOR1 mRNA expression in normal liver, hepatitis, cirrhosis and HCC tissues

NOR1 mRNA ISH was performed on all sections representing human normal liver, hepatitis, cirrhosis and HCC. Representative staining patterns for NOR1 mRNA are indicated in Fig. 1. Positive signals were detected in the cytoplasm and/or nucleus. Table I indicates the expression of NOR1 mRNA in normal liver, hepatitis, cirrhosis and HCC. The positive rate of NOR1 mRNA expression in normal liver, hepatitis and cirrhosis was 43.8, 58.3 and 65.6%, respectively. The expression of NOR1 mRNA in hepatitis and cirrhosis did not appear to be significantly different from the normal liver (P>0.05). By contrast, positive expression of NOR1 mRNA was exhibited in 25 (78.1%) HCC cases and negative expression of NOR1 mRNA was observed in the remaining 7 cases (21.9%). The positive rate of NOR1 mRNA in patients with HCC was significantly higher compared with the normal control (P=0.017).

 Expression of NOR1 protein expression normal liver, hepatitis, cirrhosis and HCC tissues

IHC was performed to examine the expression of NOR1 protein in human normal liver, hepatitis, cirrhosis and HCC. Fig. 2 shows representative staining patterns of NOR1 protein. The results indicated that NOR1 protein was expressed at variable levels, and localized within the cellular nuclei and cytoplasm.

Negative expression for NOR1 protein was observed in all normal liver samples, while the positive rate was 12.5% in hepatitis and 15.6% in cirrhotic liver samples. However, no significant difference in positive expression rate was observed between normal liver and hepatitis/cirrhotic liver samples (P>0.05).

NOR1 protein was expressed differentially between the normal liver and HCC. In a total of 32 cases of HCC, the expression of NOR1 protein was positive in 21 (65.6%) cases and negative (34.4%) in the remaining 11 cases. The positive rate of NOR1 protein expression was significantly higher in HCC tissues compared with the normal liver tissues (P<0.001; Table II).

 Correlation between NOR1 expression and clinicopathological parameters of patients with HCC

The present study also analyzed the association between NOR1 expression and clinicopathological parameters of patients with HCC. The results in Table III indicate that there was no statistically significant association between NOR1 mRNA expression and any of the clinicopathological parameters investigated (P>0.05). However, Table IV demonstrates that NOR1 protein expression was correlated with the differentiation degree and tumor-node-metastasis (TNM) (16) tumor stage of patients with HCC. The NOR1 protein positive protein expression rate was significantly higher in HCC patients with a low differentiation degree and a high TNM stage (P<0.05).

 Discussion

The NOR1 gene was initially identified in NPC by Nie et al in 2003 (11). The expression of NOR1 was downregulated in the CNE1 NPC cell line in comparison to normal nasopharyngeal epithelial cells; however, enzymatic activity was higher in the CNE1 cells compared with the normal nasopharyngeal epithelial cells. NOR1 is regulated by heat shock factor 1 and nuclear respiratory factor 1 (17), which are two stress-responsive transcription factors that have important roles in carcinogenesis (18,19). During the last decade, research regarding the association between NOR1 expression and human cancer has predominantly focused on NPC (20–22). It has been demonstrated that NOR1 is able to regulate NPC cell proliferation, apoptosis, autophagy and metabolism (20,21). In addition, a small number of studies have reported that NOR1 overexpression is associated with prostate (23) and cervical (21) cancer.

Certain in vitro studies also suggest that NOR1 may be a candidate gene for hepatocarcinogenesis. NOR1 overexpression may induce Grb2 and E-selectin expression in HepG2 cells, and activate MAPK signal transduction (12,13,24). These studies indicated that NOR1 may be important in the formation of chemical carcinogens and carcinogenesis of HCC.

The development of HCC is a multistep process with the involvement of a multifactorial etiology. It is well-established that HCC frequently arises in the setting of cirrhosis, and cirrhosis is attributable to chronic hepatitis B or C virus infection. This trend has been observed in cases in almost all countries (25–27).

In the current study, the expression of NOR1 was determined in specimens of normal liver, hepatitis, cirrhosis and HCC obtained as tissue array slides. ISH was used to detect the expression of NOR1 mRNA, whereas the expression of NOR1 protein was examined by IHC. The results indicated that NOR1 was primarily localized within the nuclei and cytoplasm.

By performing a western blot assay, Xiang et al identified that human livers exhibit an absence of NOR1 protein. Furthermore, tissue sections from the liver did not stain positive for NOR1 in an IHC assay (28). Consistent with the results in the literature, the IHC results of the present study demonstrated negative expression for NOR1 protein in all 16 normal liver specimens analyzed. However, the ISH assay revealed that the positive rate of NOR1 mRNA was 43.8% in normal liver specimens.

In a previous study by Xiang et al, the expression of human NOR1 protein expression was examined in various normal and cancerous tissues. It was observed that NOR1 expression was weak or negative in the majority of malignant cells, however, moderate to strong expression of NOR1 was displayed in liver cancer cells (29). Similarly, the present study identified a trend for increased positive rate of NOR1 protein and mRNA expression from normal liver samples to hepatitis, cirrhosis and HCC samples. However, positive NOR1 protein and mRNA expression observed in the normal liver samples was not significantly different to the hepatitis and cirrhotic liver samples. By contrast, the positive rate of NOR1 mRNA and protein expression in patients with HCC was significantly higher in comparison to the normal control. The aforementioned findings indicate a possible role of NOR1 in the progression of HCC. Furthermore, the current study identified that NOR1 protein expression correlates with certain clinicopathological parameters of HCC, including pathological stage and TNM status. The positive rate of NOR1 expression was higher in HCC patients with poor pathological differentiation grade and high TNM stage.

In conclusion, the present study examined the mRNA and protein expression of NOR1 in normal human liver, hepatitis, cirrhosis and HCC specimens, which together represent the process of HCC development. NOR1 expression was increased in HCC and its expression was correlated with clinicopathological parameters of patients with HCC. Thus, NOR1 may be involved in HCC progression and could be employed as a predictive biomarker in HCC development.

 Acknowledgements

The present study was supported by the National Natural Science Foundation of China (grant nos. 30300383, 81072270 and 81101828) and the Fundamental Research Funds for the Central Universities (grant no. 2011JQ030).

 References El-SeragHBRudolphKLHepatocellular carcinoma: Epidemiology and molecular carcinogenesisGastroenterology13225572576200710.1053/j.gastro.2007.04.06117570226 AltekruseSFMcGlynnKAReichmanMEHepatocellular carcinoma incidence, mortality and survival trends in the United States from 1975 to 2005J Clin Oncol2714851491200910.1200/JCO.2008.20.775319224838 ParkinDMBrayFFerlayJPisaniPGlobal cancer statistics, 2002CA Cancer J Clin5574108200510.3322/canjclin.55.2.7415761078 ZhangWShuXOLiHYangGCaiHJiBTGaoJGaoYTZhengWXiangYBVitamin intake and liver cancer risk: A report from two cohort studies in ChinaJ Natl Cancer Inst10411731181201210.1093/jnci/djs27722811438 TeoEKFockKMHepatocellular carcinoma: An Asian perspectiveDig Dis19263268200110.1159/00005069211935085 ZhuAXSystemic therapy of advanced hepatocellular carcinoma: How hopeful should we be?Oncologist11790800200610.1634/theoncologist.11-7-79016880238 El-SeragHBMasonACRising incidence of hepatocellular carcinoma in the United StatesN Engl J Med340745750199910.1056/NEJM19990311340100110072408 ThomasMBZhuAXHepatocellular carcinoma: The need for progressJ Clin Oncol2328922899200510.1200/JCO.2005.03.19615860847 ShirahaHYamamotoKNambaMHuman hepatocyte carcinogenesis (review)Int J Oncol4211331138201323426905 HagymásiKTulassayZEpidemiology, risk factors and molecular pathogenesis of primary liver cancerOrv Hetil1495415482008(In Hungarian)10.1556/OH.2008.2831318343770 NieXZhangBLiXXiangJXiaoBMaJZhouMZhuSLuHGuiRCloning, expression and mutation analysis of NOR1, a novel human gene down-regulated in HNE1 nasopharyngeal carcinoma cell lineJ Cancer Res Clin Oncol129410414200310.1007/s00432-003-0451-912819961 GuiRLiDQiGSuhadANieXInhibition of Grb2-mediated activation of MAPK signal transduction suppresses NOR1/CB1954-induced cytotoxicity in the HepG2 cell lineOncol Lett4566570201223741254 ShenCMNieXMLiDQScreening of genes differentially expressed in HepG2 cells transfected with NOR1 gene using DNA microarrayPractical Preventive Medicine146096112007(In Chinese) GuXFuMDingYNiHZhangWZhuYTangXXiongLLiJQiuLTIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCCPLoS One9e106161201410.1371/journal.pone.010616125171061 FriedrichsKGlubaSEidtmannHJonatWOverexpression of p53 and prognosis in breast cancerCancer7236413647199310.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-88252480 EdgeSBByrdDRComptonCCFritzAGGreeneFLTrottiAAJCC Cancer Staging Manual7thSpringerNew York2010 LiWLiXWangWLiXTanYYiMYangJMcCarthyJBXiongWWuMNOR1 is an HSF1- and NRF1-regulated putative tumor suppressor inactivated by promoter hypermethylation in nasopharyngeal carcinomaCarcinogenesis3213051314201110.1093/carcin/bgr17421803736 XuZChenLLeungLYenTSLeeCChanJYLiver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasiaProc Natl Acad Sci USA10241204125200510.1073/pnas.050066010215738389 DaiCWhitesellLRogersABLindquistSHeat shock factor 1 is a powerful multifaceted modifier of carcinogenesisCell13010051018200710.1016/j.cell.2007.07.02017889646 LiWLiXWangWYiMZhouYZhengPXiongWYangJPengSMcCarthyJBTumor suppressor gene Oxidored-nitro domain-containing protein 1 regulates nasopharyngeal cancer cell autophagy, metabolism and apoptosis in vitroInt J Biochem Cell Biol4520162026201310.1016/j.biocel.2013.06.02023831407 OuyangJWuMHuangCCaoLLiGOverexpression of oxidored-nitro domain containing protein 1 inhibits human nasopharyngeal carcinoma and cervical cancer cell proliferation and induces apoptosis: Involvement of mitochondrial apoptotic pathwaysOncol Rep297986201323124592 WangWLiXZhangWLiWYiMYangJZengZWanshuraColvin LEMcCarthyJBFanSOxidored-nitro domain containing protein 1 (NOR1) expression suppresses slug/vimentin but not snail in nasopharyngeal carcinoma: Inhibition of EMT in vitro and in vivo in miceCancer Lett348109118201410.1016/j.canlet.2014.03.00524657653 ShanZHouQZhangNGuoLZhangXMaYZhouYOverexpression of oxidored-nitro domain containing protein 1 induces growth inhibition and apoptosis in human prostate cancer PC3 cellsOncol Rep3219391946201425118646 LiYJWangWWLiDQEffect of NOR1 Gene on Level of E-selectin in HepG2 Cells and its MechanismThe Practical Journal of Cancer259122010(In Chinese) PerzJFArmstrongGLFarringtonLAHutinYJBellBPThe contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJ Hepatol45529538200610.1016/j.jhep.2006.05.01316879891 DavilaJAMorganROShaibYMcGlynnKAEl-SeragHBHepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based studyGastroenterology12713721380200410.1053/j.gastro.2004.07.02015521006 KanwalFHoangTKramerJRAschSMGoetzMBZeringueARichardsonPEl-SeragHBIncreasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infectionGastroenterology14011821188201110.1053/j.gastro.2010.12.03221184757 XiangBWangWLiWLiXLiXLiGDifferential expression of oxidored nitro domain containing protein 1 (NOR1), in mouse tissues and in normal and cancerous human tissuesGene4931826201210.1016/j.gene.2011.11.03922155709 XiangBYiMWangLLiuWZhangWOuyangJPengYLiWYinDZhouMPreparation of polyclonal antibody specific for NOR1 and detection of its expression pattern in human tissues and nasopharyngeal carcinomaActa Biochim Biophys Sin (Shanghai)41754762200910.1093/abbs/gmp06419727524

Expression of oxidored-nitro domain-containing protein 1 (NOR1) mRNA in normal liver, hepatitis, cirrhosis and HCC. (A) Negative and (B) positive expression of NOR1 mRNA in normal liver. (C) Negative and (D) positive expression of NOR1 mRNA in hepatitis. (E) Negative and (F) positive expression of NOR1 mRNA in cirrhosis. (G) Negative and (H) positive expression of NOR1 mRNA in hepatocellular carcinoma. Nitroblue tetrazolium, bromochloroindolyl phosphate and nuclear fast red staining; magnification, ×400.

Expression of oxidored-nitro domain-containing protein 1 (NOR1) protein in normal liver, hepatitis, cirrhosis and HCC, as determined by immunohistochemistry. (A) Negative expression of NOR1 protein in normal liver. (B) Negative and (C) posiitve expression of NOR1 protein in hepatitis. (D) Negative and (E) positive expression of NOR1 protein in cirrhosis. (F) Negative and (G) positive expression of NOR1 protein in hepatocellular carcinoma. 3,3′-diaminobenzidine and hematoxylin.staining; magnification, ×400.

Expression of NOR1 mRNA in normal liver, hepatitis, cirrhosis and HCC.

NOR1 mRNA expression, n (%)
Specimen type n Negative Positive χ2 P-valuea
Normal 16   9 (56.2)   7 (43.8)
Hepatitis 24 10 (41.7) 14 (58.3) 0.819 0.366
Cirrhosis 32 11 (34.4) 21 (65.6) 2.100 0.147
HCC 32   7 (21.9) 25 (78.1) 5.672 0.017

P-value vs. normal tissue. NOR1, oxidored-nitro domain-containing protein 1; HCC, hepatocellular carcinoma.

Expression of NOR1 protein in normal liver, hepatitis, cirrhosis and HCC.

NOR1 protein expression, n (%)
Specimen type n Negative Positive χ2 P-valuea
Normal 16   16 (100.0) 0 (0.0)
Hepatitis 24 21 (87.5)   3 (12.5)   2.162   0.141
Cirrhosis 32 27 (84.4)   5 (15.6)   2.791   0.095
HCC 32 11 (34.4) 21 (65.6) 18.667 <0.001

P-value vs. normal tissue. NOR1, oxidored-nitro domain-containing protein 1; HCC, hepatocellular carcinoma.

Association between NOR1 mRNA expression and clinicopathological parameters of patients with HCC.

NOR1 mRNA expression, n (%)
Feature n Negative Positive χ2 P-value
Age, years
  <50 15 4 (57.1) 11 (44.0) 0.379 0.678
  ≥50 17 3 (42.9) 14 (56.0)
Gender
  Male 24 4 (57.1) 20 (80.0) 1.524 0.327
  Female 8 3 (42.9) 5 (20.0)
HBsAg
  (+) 16 3 (27.3) 13 (61.9) 3.463 0.135
  (−) 16 8 (72.7) 8 (38.1)
Pathological stage
  I 3 2 (28.6) 1 (4.0) 4.355 0.113
  II 19 4 (57.1) 15 (60.0)
  III 10 1 (14.3) 9 (36.0)
TNM status
  I 2 1 (14.3) 1 (4.0) 1.234 0.745
  II 19 4 (57.1) 15 (60.0)
  III 10 2 (28.6) 8 (32.0)
  IV 1 0 (0.0) 1 (4.0)

NOR1, oxidored-nitro domain-containing protein 1; HCC, hepatocellular carcinoma; TNM, tumor-node-metastasis.

Association between NOR1 protein expression and clinicopathological parameters of patients with HCC.

NOR1 protein expression, n (%)
Feature n Negative Positive χ2 P-value
Age, years
  <50 15 4 (36.4) 11 (52.4) 0.744 0.472
  ≥50 17 7 (63.6) 10 (47.6)
Gender
  Male 24 6 (54.5) 18 (85.7) 3.740 0.088
  Female   8 5 (45.5) 3 (14.3)
HBsAg
  (+) 16 4 (57.1) 12 (48.0) 0.183 1.000
  (−) 16 3 (42.9) 13 (52.0)
Pathological stage
  I   3 3 (27.3) 0 (0.0) 6.709 0.035
  II 19 6 (54.5) 13 (61.9)
  III 10 2 (18.2) 8 (38.1)
TNM status
  I   2 2 (18.2) 0 (0.0) 11.002 0.012
  II 19 9 (81.8) 10 (47.6)
  III 10 0 (0.0) 10 (47.6)
  IV   1 0 (0.0) 1 (4.8)

NOR1, oxidored-nitro domain-containing protein 1; HCC, hepatocellular carcinoma; TNM, tumor-node-metastasis.